Medline (NASDAQ:MDLN – Get Free Report) shares gapped down before the market opened on Wednesday . The stock had previously closed at $37.70, but opened at $36.28. Medline shares last traded at $36.2490, with a volume of 674,864 shares traded.
Analysts Set New Price Targets
MDLN has been the topic of a number of recent research reports. Evercore restated an “outperform” rating and set a $55.00 price objective on shares of Medline in a research note on Wednesday, February 25th. Royal Bank Of Canada upped their target price on shares of Medline from $47.00 to $53.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Wells Fargo & Company upped their target price on shares of Medline from $42.00 to $47.00 and gave the company an “equal weight” rating in a research note on Friday, February 27th. Stifel Nicolaus set a $55.00 target price on shares of Medline in a research note on Wednesday, February 25th. Finally, Citigroup decreased their target price on shares of Medline from $60.00 to $55.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $50.85.
View Our Latest Stock Analysis on Medline
Medline Price Performance
Medline (NASDAQ:MDLN – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.33 earnings per share for the quarter, beating analysts’ consensus estimates of $0.29 by $0.04. The business had revenue of $7.35 billion for the quarter. The firm’s revenue for the quarter was up 10.7% on a year-over-year basis. As a group, research analysts forecast that Medline will post 1.5 earnings per share for the current year.
Hedge Funds Weigh In On Medline
A number of hedge funds have recently bought and sold shares of the company. Mass General Brigham Inc acquired a new stake in shares of Medline during the 4th quarter valued at approximately $1,104,000. Baillie Gifford & Co. acquired a new stake in shares of Medline during the 4th quarter valued at approximately $437,236,000. UBS Group AG acquired a new stake in shares of Medline during the 4th quarter valued at approximately $54,707,000. Massachusetts Financial Services Co. MA acquired a new stake in shares of Medline during the 4th quarter valued at approximately $429,544,000. Finally, Pictet Asset Management Holding SA acquired a new stake in shares of Medline during the 4th quarter valued at approximately $48,996,000.
Medline Company Profile
Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.
In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.
Featured Articles
- Five stocks we like better than Medline
- The Great AI Rotation: Cashing In on Data
- Mirum Pharma: A Rare Disease Growth Story to Watch
- The Great Cloud Divide: How AI Is Reshuffling the Software Deck
- Eagle Materials: A Dividend-Paying Brick & Mortar AI Play
Receive News & Ratings for Medline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medline and related companies with MarketBeat.com's FREE daily email newsletter.
